Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Bryon D. Johnson PhD

Bryon D. Johnson PhD profile photo picture


Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center
Member of the Center for Disease Prevention Research (CDPR)
Member of the Center for Immunology

Publications (109)

  • The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. (Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM) Brain Behav Immun Health 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022    
  • Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. (Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN) Cytotherapy 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022    
  • Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. (Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN) JAMA Oncol 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022       2 Citations
  • Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. (Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M) Adv Sci (Weinh) 2022 Apr;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022       3 Citations
  • Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. (Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS) J Cancer Prev 2021 Dec 30;26(4):309-317 PMID: 35047458 PMCID: PMC8749317 01/21/2022    
  • Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? (Palen K, Zurko J, Johnson BD, Hari P, Shah NN) Cytotherapy 2021 Nov;23(11):985-990 PMID: 34538575 SCOPUS ID: 2-s2.0-85115015094 09/21/2021       3 Citations
  • Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. (Pan J, Chen Y, Zhang Q, Khatun A, Palen K, Xin G, Wang L, Yang C, Johnson BD, Myers CR, Sei S, Shoemaker RH, Lubet RA, Wang Y, Cui W, You M) Commun Biol 2021 Jul 23;4(1):906 PMID: 34302042 PMCID: PMC8302676 SCOPUS ID: 2-s2.0-85111091265 07/25/2021       5 Citations
  • Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. (AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB) iScience 2021 Jun 25;24(6):102653 PMID: 34189432 PMCID: PMC8220235 SCOPUS ID: 2-s2.0-85107963806 07/01/2021       4 Citations
  • Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression (AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB) iScience 25 June 2021;24(6) SCOPUS ID: 2-s2.0-85107963806 06/25/2021       4 Citations
  • PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. (Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN) Haematologica 2021 Oct 01;106(10):2788-2790 PMID: 33853295 PMCID: PMC8485669 SCOPUS ID: 2-s2.0-85116219490 04/16/2021       1 Citation
  • Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. (Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A) J Cancer Prev 2021 Mar 30;26(1):71-82 PMID: 33842408 PMCID: PMC8020174 04/13/2021    
  • STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. (Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB) Cell Mol Gastroenterol Hepatol 2021;12(1):41-58 PMID: 33548597 PMCID: PMC8081932 SCOPUS ID: 2-s2.0-85104314508 02/07/2021       15 Citations
  • Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system. (Lenarczyk M, Laiakis EC, Mattson DL, Johnson BD, Kronenberg A, North PE, Komorowski R, Mäder M, Baker JE) FASEB Bioadv 2020 Dec;2(12):705-719 PMID: 33336158 PMCID: PMC7734425 SCOPUS ID: 2-s2.0-85101816410 12/19/2020       3 Citations
  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020       146 Citations
  • Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. (Badar T, Johnson BD, Hamadani M) Bone Marrow Transplant 2021 Mar;56(3):683-685 PMID: 32782349 SCOPUS ID: 2-s2.0-85089247553 08/13/2020       3 Citations
  • Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020       7 Citations
  • Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. (Shah NN, Jerkins JH, Johnson BD, Hari P) JCO Oncol Pract 2020 Sep;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020       1 Citation
  • Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. (Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P) Blood Adv 2020 May 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020       21 Citations
  • Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator (Pan J, Zhang Q, Palen K, Wang L, Qiao L, Johnson B, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M) EBioMedicine November 2019;49:72-81 SCOPUS ID: 2-s2.0-85074132937 11/01/2019       18 Citations
  • Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. (Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q) Blood Adv 2019 Oct 22;3(20):3099-3110 PMID: 31648333 PMCID: PMC6849959 SCOPUS ID: 2-s2.0-85074935557 10/28/2019       16 Citations
  • An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019       1 Citation
  • STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. (Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB) J Immunother Cancer 2019 Apr 29;7(1):115 PMID: 31036082 PMCID: PMC6489306 SCOPUS ID: 2-s2.0-85065258266 05/01/2019       60 Citations
  • A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019       16 Citations
  • Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. (Shah NN, Maatman T, Hari P, Johnson B) Front Oncol 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019       99 Citations
  • A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. (Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA) Cancer Epidemiol Biomarkers Prev 2019 Apr;28(4):680-689 PMID: 30530849 PMCID: PMC6545232 SCOPUS ID: 2-s2.0-85063867816 12/12/2018       2 Citations
  • Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8+ T cells. (Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ) J Leukoc Biol 2018 Nov;104(5):883-893 PMID: 30063264 PMCID: PMC6195461 SCOPUS ID: 2-s2.0-85053248137 08/01/2018       9 Citations
  • Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. (Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ) Immunohorizons 2018 Apr 01;2(4):107-118 PMID: 30027154 PMCID: PMC6048965 SCOPUS ID: 2-s2.0-85075290149 07/22/2018       9 Citations
  • Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy. (Palen K, Thakar M, Johnson BD, Gershan JA) J Pediatr Hematol Oncol 2019 Nov;41(8):648-652 PMID: 29912035 PMCID: PMC6855330 SCOPUS ID: 2-s2.0-85048631854 06/19/2018       1 Citation
  • Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA) BMC Cancer 2018 Mar 27;18(1):335 PMID: 29587663 PMCID: PMC5870823 SCOPUS ID: 2-s2.0-85044523365 03/29/2018       178 Citations
  • Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018       33 Citations
  • T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. (Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ) Cancer Res 2017 Oct 15;77(20):5676-5686 PMID: 28916658 SCOPUS ID: 2-s2.0-85031429221 09/17/2017       13 Citations
  • Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice. (Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD) J Immunother Cancer 2017;5:51 PMID: 28642819 PMCID: PMC5477110 SCOPUS ID: 2-s2.0-85021161579 06/24/2017       16 Citations
  • Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. (Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cui W) Proc Natl Acad Sci U S A 2017 Jan 24;114(4):740-745 PMID: 28069963 PMCID: PMC5278465 SCOPUS ID: 2-s2.0-85010648441 01/11/2017       18 Citations
  • Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse (Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, Johnson BD, LeFever AV) Cellular Immune Mechanisms and Tumor Dormancy 1 January 2017:111-132 SCOPUS ID: 2-s2.0-1842343134 01/01/2017       6 Citations
  • Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. (Riese MJ, Moon EK, Johnson BD, Albelda SM) Front Cell Dev Biol 2016;4:108 PMID: 27800476 PMCID: PMC5065962 SCOPUS ID: 2-s2.0-85058010526 11/02/2016       33 Citations
  • E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. (Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA) Oncotarget 2016 Jul 12;7(28):43363-43375 PMID: 27270319 PMCID: PMC5190029 SCOPUS ID: 2-s2.0-84978710944 06/09/2016       12 Citations
  • Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. (Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, Dwinell MB, Kalyanaraman B) Cancer Res 2016 Jul 01;76(13):3904-15 PMID: 27216187 PMCID: PMC4930686 SCOPUS ID: 2-s2.0-84977588183 05/25/2016       126 Citations
  • Erratum to: Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. (Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA) Cancer Microenviron 2016 Apr;9(1):75 PMID: 26747049 PMCID: PMC4842184 SCOPUS ID: 2-s2.0-84953410846 01/10/2016    
  • p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. (Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, Johnson B, Dwinell MB, Chitambar CR, Chen G) Stem Cells 2015 Sep;33(9):2738-47 PMID: 26077647 PMCID: PMC4792188 SCOPUS ID: 2-s2.0-84940467357 06/17/2015       24 Citations
  • Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. (Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD) J Immunother Cancer 2015;3(1):2 PMID: 25614821 PMCID: PMC4302511 SCOPUS ID: 2-s2.0-84977111467 01/24/2015       86 Citations
  • Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer (Barr KM, Gershan JA, Johnson BD) Cancer Immunology: Bench to Bedside Immunotherapy of Cancers 1 January 2015:189-201 SCOPUS ID: 2-s2.0-84943638413 01/01/2015    
  • Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. (Kearl TJ, Jing W, Gershan JA, Johnson BD) J Immunol 2013 Jun 01;190(11):5620-8 PMID: 23616570 PMCID: PMC3891840 SCOPUS ID: 2-s2.0-84878099006 04/26/2013       81 Citations
  • Endothelial and Accessory Cell Interactions in Neuroblastoma Tumor Microenvironment (Chapter Title) (Jill Gershan, Andrew Chan, Magdalena Chrzanowska-Wodnicka, Bryon Johnson, Qing Robert Miao and Ramani Ramchandran) Research Directions in Tumor Angiogenesis (Book Title) ISBN: 978-953-51-0963-1 02/06/2013    
  • Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. (Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S) J Cancer Res Clin Oncol 2013 May;139(5):727-37 PMID: 23354841 SCOPUS ID: 2-s2.0-84876297557 01/29/2013       28 Citations
  • Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. (Barr KM, Jing W, Hallett WH, Gershan JA, Johnson BD) J Immunother 2013 Jan;36(1):41-51 PMID: 23211619 PMCID: PMC3521867 SCOPUS ID: 2-s2.0-84871929138 12/06/2012       2 Citations
  • HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Johnson B, See WA) J Urol 2013 Apr;189(4):1541-6 PMID: 23041342 SCOPUS ID: 2-s2.0-84875940317 10/09/2012       7 Citations
  • Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo. (Yan X, Doffek K, Yin C, Krein M, Phillips M, Sugg SL, Johnson B, Shilyansky J) Cancer Immunol Immunother 2012 Nov;61(11):1917-27 PMID: 22476407 SCOPUS ID: 2-s2.0-84870984151 04/06/2012       11 Citations
  • Exciting new murine model of cGVHD. (Johnson BD) Blood 2012 Feb 09;119(6):1331-2 PMID: 22323409 SCOPUS ID: 2-s2.0-84856832037 02/11/2012       1 Citation
  • Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. (Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA) Cancer Microenviron 2013 Apr;6(1):79-89 PMID: 22237886 PMCID: PMC3601216 SCOPUS ID: 2-s2.0-84875235812 01/13/2012       4 Citations
  • Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45 PMID: 21536144 SCOPUS ID: 2-s2.0-79960218752 05/04/2011       130 Citations
  • Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. (Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD) Blood 2011 Jun 23;117(25):6952-62 PMID: 21521781 PMCID: PMC3128485 SCOPUS ID: 2-s2.0-79959507720 04/28/2011       34 Citations
  • Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3+CD4+CD25+ natural regulatory T cells (Xia G, Zhang Z, Johnson BD) Heart Transplantation: Indications and Contraindications, Procedures and Complications January 2011:25-49 SCOPUS ID: 2-s2.0-84895291113 01/01/2011    
  • Exploiting arginase to prevent GVHD (Hallett W, Johnson B) Blood 16 December 2010;116(25):5440-5441 SCOPUS ID: 2-s2.0-78650476237 12/16/2010    
  • Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. (Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S) Anticancer Res 2010 Sep;30(9):3313-9 PMID: 20944103 SCOPUS ID: 2-s2.0-77958574557 10/15/2010       15 Citations
  • Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. (Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ) Cancer Sci 2010 Nov;101(11):2316-24 PMID: 20718755 PMCID: PMC3103783 SCOPUS ID: 2-s2.0-78049437902 08/20/2010       6 Citations
  • Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. (Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ) Cell Immunol 2010;265(1):65-73 PMID: 20692654 PMCID: PMC2935508 SCOPUS ID: 2-s2.0-77956171011 08/10/2010       4 Citations
  • Robert Truitt tribute. (Johnson B, Drobyski W, Blazar B, Korngold R) Biol Blood Marrow Transplant 2010 Jan;16(1):143-4 PMID: 19836456 SCOPUS ID: 2-s2.0-77949880015 10/20/2009    
  • Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. (Jing W, Gershan JA, Johnson BD) Blood 2009 Apr 30;113(18):4449-57 PMID: 19182203 PMCID: PMC2676098 SCOPUS ID: 2-s2.0-66149140993 02/03/2009       36 Citations
  • Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3+CD4+CD25+ natural regulatory T cells (Xia G, Zhang Z, Johnson BD) Heart Transplantation: Indications and Contradictions, Procedures and Complications 1 January 2009:25-49 SCOPUS ID: 2-s2.0-85034977492 01/01/2009    
  • Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. (Yan X, Johnson BD, Orentas RJ) J Immunol 2008 Oct 01;181(7):4621-31 PMID: 18802064 PMCID: PMC2975591 SCOPUS ID: 2-s2.0-58149277748 09/20/2008       14 Citations
  • Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. (Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD) J Immunol 2008 Aug 01;181(3):1877-86 PMID: 18641325 PMCID: PMC3804024 SCOPUS ID: 2-s2.0-49649104777 07/22/2008       33 Citations
  • Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. (Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR) Blood 2007 Nov 15;110(10):3804-13 PMID: 17693581 PMCID: PMC2077325 SCOPUS ID: 2-s2.0-36348980530 08/19/2007       195 Citations
  • Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. (Zhou Q, Johnson BD, Orentas RJ) Cell Immunol 2007 Feb;245(2):91-102 PMID: 17543914 PMCID: PMC1949498 SCOPUS ID: 2-s2.0-34250349688 06/05/2007       5 Citations
  • CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. (Johnson BD, Jing W, Orentas RJ) J Immunother 2007;30(2):203-14 PMID: 17471167 SCOPUS ID: 2-s2.0-34247588130 05/02/2007       52 Citations
  • Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. (Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A) Cytotherapy 2007;9(2):144-57 PMID: 17453966 SCOPUS ID: 2-s2.0-34047130792 04/25/2007       40 Citations
  • Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. (Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ) BMC Immunol 2007 Mar 30;8:4 PMID: 17397536 PMCID: PMC1852119 SCOPUS ID: 2-s2.0-34247279752 04/03/2007       11 Citations
  • Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models (Jing W, Johnson BD) Cancer Vaccines and Tumor Immunity 1 March 2007:205-215 SCOPUS ID: 2-s2.0-84890987859 03/01/2007    
  • Cancer Vaccines: Progress and Promise (Orentas RJ, Johnson B, Hodge J) Cancer Vaccines and Tumor Immunity 1 March 2007:1-11 SCOPUS ID: 2-s2.0-84891019701 03/01/2007    
  • Cancer Vaccines and Tumor Immunity (Orentas R, Hodge JW, Johnson BD) Cancer Vaccines and Tumor Immunity 1 March 2007:1-334 SCOPUS ID: 2-s2.0-84890996589 03/01/2007       3 Citations
  • Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. (Jing W, Orentas RJ, Johnson BD) Biol Blood Marrow Transplant 2007 Mar;13(3):277-92 PMID: 17317581 PMCID: PMC1852542 SCOPUS ID: 2-s2.0-33847016412 02/24/2007       19 Citations
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID: 17269937 SCOPUS ID: 2-s2.0-33846453333 02/03/2007       107 Citations
  • Immune response modulation by curcumin in a latex allergy model. (Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN) Clin Mol Allergy 2007 Jan 25;5:1 PMID: 17254346 PMCID: PMC1796894 SCOPUS ID: 2-s2.0-33847210623 01/27/2007       65 Citations
  • Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. (Xia G, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2006 Apr;12(4):397-407 PMID: 16545723 SCOPUS ID: 2-s2.0-33644898608 03/21/2006       55 Citations
  • Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. (Yan X, Orentas RJ, Johnson BD) Cytokine 2006 Feb 21;33(4):188-98 PMID: 16522371 PMCID: PMC2018658 SCOPUS ID: 2-s2.0-33646468680 03/09/2006       35 Citations
  • Suppression of anti-cancer immunity by regulatory T cells: back to the future. (Orentas RJ, Kohler ME, Johnson BD) Semin Cancer Biol 2006 Apr;16(2):137-49 PMID: 16376101 SCOPUS ID: 2-s2.0-31644451518 12/27/2005       61 Citations
  • The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice. (Barrios CS, Johnson BD, D Henderson J Jr, Fink JN, Kelly KJ, Kurup VP) Clin Exp Immunol 2005 Nov;142(2):242-50 PMID: 16232210 PMCID: PMC1809515 SCOPUS ID: 2-s2.0-27644433870 10/20/2005       13 Citations
  • Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. (Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ) J Immunother 2005;28(5):449-60 PMID: 16113601 SCOPUS ID: 2-s2.0-24144487135 08/23/2005       31 Citations
  • Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. (Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA) Blood 2005 Oct 15;106(8):2671-9 PMID: 15972454 PMCID: PMC1895311 SCOPUS ID: 2-s2.0-27144537145 06/24/2005       74 Citations
  • Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. (Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ) Genet Vaccines Ther 2005 Jun 21;3(1):4 PMID: 15969754 PMCID: PMC1182385 SCOPUS ID: 2-s2.0-27344454702 06/23/2005       5 Citations
  • Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. (Xia G, Kovochich M, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2004 Nov;10(11):748-60 PMID: 15505606 SCOPUS ID: 2-s2.0-6444235650 10/27/2004       25 Citations
  • The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. (Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL, Johnson BD) Cell Immunol 2004 Feb;227(2):129-39 PMID: 15135295 SCOPUS ID: 2-s2.0-2342634326 05/12/2004       17 Citations
  • Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. (Yan X, Johnson BD, Orentas RJ) Immunology 2004 May;112(1):105-16 PMID: 15096190 PMCID: PMC1782467 SCOPUS ID: 2-s2.0-2342604967 04/21/2004       28 Citations
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID: 14675082 SCOPUS ID: 2-s2.0-1542544992 12/17/2003       48 Citations
  • CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. (Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL) Blood 2004 Apr 01;103(7):2691-8 PMID: 14644999 SCOPUS ID: 2-s2.0-1642414806 12/03/2003       66 Citations
  • Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. (Johnson BD, Yan X, Schauer DW, Orentas RJ) Cell Immunol 2003 Mar;222(1):15-26 PMID: 12798304 SCOPUS ID: 2-s2.0-0038207050 06/12/2003       26 Citations
  • Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. (Johnson BD, Taylor PA, Stankowski MC, Talib S, Hearst JE, Blazar BR) Biol Blood Marrow Transplant 2002;8(11):581-7 PMID: 12463476 SCOPUS ID: 2-s2.0-6444245313 12/05/2002    
  • CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. (Johnson BD, Konkol MC, Truitt RL) Biol Blood Marrow Transplant 2002;8(10):525-35 PMID: 12434947 SCOPUS ID: 2-s2.0-0036435911 11/19/2002       81 Citations
  • Production of macrophage migration inhibitory factor by human and murine neuroblastoma. (Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ) Tumour Biol 2002;23(3):123-9 PMID: 12218292 SCOPUS ID: 2-s2.0-0036559387 09/10/2002       18 Citations
  • Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. (Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL) Biol Blood Marrow Transplant 2001;7(11):589-95 PMID: 11760146 SCOPUS ID: 2-s2.0-0035195863 01/05/2002       11 Citations
  • Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. (Orentas RJ, Schauer D, Bin Q, Johnson BD) Cell Immunol 2001 Oct 10;213(1):4-13 PMID: 11747351 SCOPUS ID: 2-s2.0-0035841263 12/19/2001       55 Citations
  • T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. (Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP) Clin Immunol 2001 Aug;100(2):228-35 PMID: 11465952 SCOPUS ID: 2-s2.0-0034909982 07/24/2001       26 Citations
  • Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). (Banerjee B, Kurup VP, Greenberger PA, Johnson BD, Fink JN) Clin Exp Allergy 2001 May;31(5):761-70 PMID: 11422136 SCOPUS ID: 2-s2.0-0034840298 06/26/2001       47 Citations
  • Purified and recombinant latex proteins stimulate peripheral blood lymphocytes of latex allergic patients. (Johnson BD, Kurup VP, Sussman GL, Arif SA, Kelly KJ, Beezhold DH, Fink JN) Int Arch Allergy Immunol 1999 Dec;120(4):270-9 PMID: 10640910 SCOPUS ID: 2-s2.0-0033452670 01/21/2000       21 Citations
  • Experimental animal models in the study of GVL reactions (Truitt RL, Johnson BD, Korngold R, Townsend R, Blazar BR) Allogeneic Immunotherapy for Malignant Diseases 1 January 2000:39-74 SCOPUS ID: 2-s2.0-0006857807 01/01/2000       1 Citation
  • Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. (Johnson BD, Becker EE, LaBelle JL, Truitt RL) J Immunol 1999 Dec 15;163(12):6479-87 PMID: 10586039 SCOPUS ID: 2-s2.0-0032741541 12/10/1999       62 Citations
  • Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. (Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE) J Immunol 1999 Nov 01;163(9):5145-56 PMID: 10528221 SCOPUS ID: 2-s2.0-0032711448 10/21/1999       47 Citations
  • Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32 PMID: 10392958 SCOPUS ID: 2-s2.0-0032616043 07/07/1999       54 Citations
  • Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. (Johnson BD, Hanke CA, Becker EE, Truitt RL) Cell Immunol 1998 Nov 01;189(2):149-59 PMID: 9790729 SCOPUS ID: 2-s2.0-0032211707 10/29/1998       12 Citations
  • The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. (Johnson BD, Hanke CA, Truitt RL) Leuk Lymphoma 1996 Sep;23(1-2):1-9 PMID: 9021679 SCOPUS ID: 2-s2.0-0029803984 09/01/1996       13 Citations
  • Principles of graft-vs.-leukemia reactivity. (Truitt RL, Johnson BD) Biol Blood Marrow Transplant 1995 Dec;1(2):61-8 PMID: 9118293 SCOPUS ID: 2-s2.0-0029421456 12/01/1995       62 Citations
  • Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. (Johnson BD, Truitt RL) Blood 1995 Jun 01;85(11):3302-12 PMID: 7756664 SCOPUS ID: 2-s2.0-0029068065 06/01/1995       134 Citations
  • Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. (Johnson BD, McCabe C, Hanke CA, Truitt RL) J Immunol 1995 May 15;154(10):5542-54 PMID: 7730653 SCOPUS ID: 2-s2.0-0028989604 05/15/1995       40 Citations
  • Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). (Wierda WG, Johnson BD, Dato ME, Kim YB) J Immunol 1993 Dec 15;151(12):7117-27 PMID: 8258715 SCOPUS ID: 2-s2.0-0027140285 12/15/1993       15 Citations
  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36 PMID: 8485480 SCOPUS ID: 2-s2.0-0027537527 04/01/1993       130 Citations
  • Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. (Wierda WG, Johnson BD, Dato ME, Kim YB) Cell Immunol 1993 Feb;146(2):270-83 PMID: 8174170 SCOPUS ID: 2-s2.0-0027408731 02/01/1993       11 Citations
  • A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. (Johnson BD, Truitt RL) Transplantation 1992 Jul;54(1):104-12 PMID: 1631918 SCOPUS ID: 2-s2.0-0026763856 07/01/1992       50 Citations
  • Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. (Johnson BD, Wierda WG, Kim YB) Cell Immunol 1991 May;134(2):378-89 PMID: 2021974 SCOPUS ID: 2-s2.0-0025851601 05/01/1991       9 Citations
  • Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). (Johnson BD, Kim YB) Cell Immunol 1990 Jan;125(1):107-19 PMID: 2293895 SCOPUS ID: 2-s2.0-0025093501 01/01/1990       11 Citations
  • C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. (Baum LL, Johnson B, Berman S, Graham D, Mold C) Immunology 1987 May;61(1):93-9 PMID: 3583316 PMCID: PMC1453307 SCOPUS ID: 2-s2.0-0023229305 05/01/1987       15 Citations
  • Last update: 12/02/2022